Tesofensine
Triple monoamine reuptake inhibitor (NE/DA/5-HT). Not a peptide — small molecule. Reduces appetite via central monoaminergic pathways.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Originally a NeuroSearch Alzheimer/Parkinson candidate. Phase 2 obesity trial (Astrup 2008) showed strong weight loss but blood-pressure and tachycardia signals. Currently approved in Mexico as Tesomet (with metoprolol). Not FDA-approved.
Not a peptide; included for stack context. Cardiovascular safety signals from Phase 2 are real. Mexican Tesomet approval is contingent on combined metoprolol — solo tesofensine carries higher BP/HR risk.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- CLimited evidence
Tesofensine — primary mechanism: triple monoamine reuptake inhibitor (ne/da/5-ht). not a peptide — small molecule. reduces appetite via central monoaminergic pathways.
1 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Approved in MX (Tesomet); not FDA-approved